FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Abstract Full Text

Article: Lawrence J et al. Structured Treatment Interruption in Patients with Multidrug-Resistant Human Immunodeficiency Virus. N Engl J Med 2003;349(9):837-46.

Supplementary Appendix 1. Definition of Multidrug-Resistant Virus

According to the protocol, multidrug-resistant HIV was defined in one of two ways: as a virus with broad resistance to protease inhibitors combined with broad resistance to either nonnucleoside reverse-transcriptase inhibitors or nucleoside reverse-transcriptase inhibitors or both, or as a virus with broad resistance to both nonnucleoside reverse-transcriptase inhibitors and nucleoside reverse-transcriptase inhibitors and at least one major protease-inhibitor resistance mutation. Broad resistance to protease inhibitors was defined by the presence of at least two of the following major mutations in the protease gene: 90M, 48V, 82A/F/T, 84V, 46I/L, and 50V. Broad resistance to nonnucleoside reverse-transcriptase inhibitors was defined by the presence of the 103N or 181C resistance mutation or at least two of the following mutations: 101E, 106A, 108I, 181I, 188C, and 190A/S. Broad resistance to nucleoside reverse-transcriptase inhibitors was defined by the presence of the 151M or 69S(XX) insertion mutation or 215Y/F in combination with at least one of the following mutations: 184V, 74V, 65R, and 69D.

Abstract Full Text